A Phase 3 interventional study of Roflumilast and Roflumilast Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 2 sites in Slovakia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-20.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 26th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,323 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 25th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 76 in phase 3, and was the 150th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week main period, and to evaluate if participants who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD similar to that observed in other participants with the 500 μg OD dose.
Roflumilast is a product which has been approved for the treatment of severe chronic obstructive lung disease (COPD) and its approved dose is 500μg once daily. This study is primarily designed to see whether alternation in this dose can improve tolerability of Roflumilast in COPD patients. Therefore one in three patients will start roflumilast therapy at a lower dose of 250μg once daily, another one in three will only take the 500μg tablet every other day (and one placebo every other day). Rest of them will start the regular dose of 500μg once daily right away and see whether starting with a lower dose of Roflumilast will lead to better tolerability. Furthermore, the study will see if patients who do not tolerate roflumilast should be given a lower dose of 250μg once daily.
Lastly, the study will investigate what the body does to roflumilast. Patients with a history of COPD for at least last 12 months and a former smoker or current smoker with history of at least 10 pack years will be invited to participate.
The main study period lasts for a maximum of 15 weeks and patients will have to visit the study site up to 6 times. If patients are not tolerating roflumilast, the investigators may switch them to the down titration period where they may be on a lower dose for rest of the study. Then patients will remain in the down titration period for additional 8 weeks and will have to visit the study site 4 times. Most of the visits will take approximately 1 to 2 hours. However, one visit in the main period and 1 or 2 visits in the down titration period will take approximately 6 to 7 hours. These visits are longer to allow time to conduct blood taking.
The Randomization visit is considered the Baseline visit and for participants that discontinue the Main Period and continue into the Down-Titration Period Day 1 of Down Titration is considered BaselineDT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Criteria affecting the read-out parameters of the study
Has taken roflumilast within 6 months of Screening (Visit V0).
Criteria within ethical considerations in terms of general health
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
Drug: Roflumilast · Drug: Standard of Care COPD Treatment
Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
Drug: Roflumilast · Drug: Roflumilast Placebo · Drug: Standard of Care COPD Treatment
Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.
Drug: Roflumilast · Drug: Standard of Care COPD Treatment
Roflumilast tablets
Also known as: Daxas, Daliresp, Libertek
Roflumilast placebo-matching tablets
The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason
The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.
Time frame: Baseline to Week 12 (Main Period)
Percentage of Participants With Adverse Events of Interest
Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.
Time frame: Baseline to Week 12 (Main Period)
Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.
Time frame: Baseline (V0DT) [assessment at end of main period] and Final Visit of Down-Titration Period (Up to Day 56)
Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period
Time frame: Baseline DT (Day 1 of Down-Titration Period) to Week 8 (Down-Titration Period)
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
Time frame: Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
Time frame: Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
Time frame: Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
Time frame: Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)
Change From Baseline in Treatment Satisfaction Scores During the Main Period
Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.
Time frame: Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)
Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period
Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.
Time frame: Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)
Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide
PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide
PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide
PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide
PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Total PDE4 Inhibitory Activity (tPDE4i)
tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.
Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)
tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.
Median Simulated Percentage of Participants With Adverse Events of Interest
The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)\] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. AEIs: 12 Weeks
Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12
The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility\] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. FEV-1: Pre-dose and Weeks 4 and 12
Participants took part in the study at 161 investigative sites in Bulgaria, Germany, Greece, Hungary, Korea, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Spain, Thailand, Ukraine and the United Kingdom from 30 April 2014 to 21 October 2015.
| Milestone | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Started | 441 | 439 | 443 |
| Safety analysis set: received study drug | 441 | 437 | 443 |
| Completed | 360 | 349 | 334 |
| Not completed | 81 | 90 | 109 |
| Withdrew: Pre-treatment event/adverse event | 44 | 57 | 68 |
| Withdrew: Major/significant protocol deviation | 0 | 1 | 3 |
| Withdrew: Lost to follow-up | 4 | 2 | 1 |
| Withdrew: Voluntary withdrawal | 23 | 23 | 21 |
| Withdrew: Lack of efficacy | 2 | 0 | 0 |
| Withdrew: Reason not specified | 8 | 5 | 16 |
| Withdrew: Did not receive study drug | 0 | 2 | 0 |
| Milestone | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Started | 27 | 39 | 38 |
| Safety analysis set: received study drug | 27 | 39 | 38 |
| Completed | 20 | 28 | 31 |
| Not completed | 7 | 11 | 7 |
| Withdrew: Pre-treatment event/adverse event | 4 | 10 | 3 |
| Withdrew: Voluntary withdrawal | 2 | 1 | 2 |
| Withdrew: Reason not specified | 1 | 0 | 2 |
The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.
| percentage of participants | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason | 18.4 | 20.1 | 24.6 |
Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.
| percentage of participants | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Percentage of Participants With Adverse Events of Interest | 45.4 | 48.3 | 54.2 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.
| Liters | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|
| Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period | 0.030 ± 0.2294 | 0.055 ± 0.4170 | 0.007 ± 0.3555 |
| percentage of participants | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|
| Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period | 25.9 | 28.2 | 18.4 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
| Liters | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|
| Day 14 (n=20, 32, 34) | 0.128 ± 0.3708 | 0.223 ± 0.4101 | 0.097 ± 0.2532 |
| Day 28 (n=20, 29, 31) | 0.162 ± 0.4274 | 0.218 ± 0.4443 | 0.070 ± 0.2067 |
| Day 56 (n=26, 39, 38) | 0.162 ± 0.3311 | 0.261 ± 0.4616 | 0.127 ± 0.3334 |
FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
| Liters | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Day 15 (n=409, 406, 386) | 0.067 ± 0.2299 | 0.094 ± 0.2573 | 0.094 ± 0.2566 |
| Day 29 (n=402, 389, 365) | 0.099 ± 0.2605 | 0.115 ± 0.2629 | 0.116 ± 0.2440 |
| Day 57 (n=376, 367, 352) | 0.104 ± 0.2659 | 0.161 ± 0.2765 | 0.133 ± 0.2705 |
| Day 84 (n=402, 411, 409) | 0.117 ± 0.2690 | 0.141 ± 0.2882 | 0.122 ± 0.2705 |
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
| Liters | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Day 15 (n=409, 406, 386) | 0.096 ± 0.4053 | 0.112 ± 0.4168 | 0.104 ± 0.4166 |
| Day 29 (n=402, 389, 365) | 0.139 ± 0.3826 | 0.143 ± 0.4172 | 0.149 ± 0.4173 |
| Day 57 (n=376, 367, 352) | 0.156 ± 0.4346 | 0.194 ± 0.4974 | 0.162 ± 0.4341 |
| Day 84 (n=402, 411, 409) | 0.157 ± 0.4746 | 0.207 ± 0.4925 | 0.147 ± 0.4555 |
Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
| Liters | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|
| Day 14 (n=20, 32, 34) | 0.087 ± 0.5392 | 0.303 ± 0.5103 | 0.104 ± 0.4568 |
| Day 28 (n=20, 29, 31) | 0.125 ± 0.6151 | 0.191 ± 0.4780 | 0.067 ± 0.3522 |
| Day 56 (n=26, 39, 38) | 0.167 ± 0.5492 | 0.113 ± 0.5100 | 0.029 ± 0.4628 |
Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.
| score on a scale | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD |
|---|---|---|---|
| Day 15 (n=410, 408, 386) | -0.4 ± 1.12 | -0.3 ± 1.15 | -0.3 ± 1.07 |
| Day 29 (n=403, 390, 366) | -0.5 ± 1.23 | -0.5 ± 1.16 | -0.5 ± 1.22 |
| Day 57 (n=375, 369, 351) | -0.6 ± 1.24 | -0.6 ± 1.26 | -0.5 ± 1.29 |
| Day 84 (n=407, 416, 412) | -0.5 ± 1.43 | -0.5 ± 1.51 | -0.3 ± 1.52 |
Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.
| score on a scale | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|
| Day 14 (n=20, 32, 34) | -1.1 ± 1.85 | -0.8 ± 1.57 | -0.8 ± 1.84 |
| Day 28 (n=20, 29, 31) | -1.2 ± 2.01 | -0.8 ± 1.75 | -0.9 ± 1.81 |
| Day 56 (n=26, 39, 38) | -0.8 ± 2.23 | -0.3 ± 2.15 | -0.4 ± 2.26 |
PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
| units per hour (1/h) | All PK Participants_Roflumilast | All PK Participants_Roflumilast N-oxide |
|---|---|---|
| Weight=33.5 kg | 0.90 | 0.57 |
| Weight=70 kg | 0.90 | 0.57 |
| Weight=160 kg | 0.90 | 0.57 |
| Age=40 | 0.90 | 0.57 |
| Age=60 | 0.90 | 0.57 |
| Age=92 | 0.90 | 0.57 |
| Smoking=former | 0.90 | 0.57 |
| Smoking=current | 0.90 | 0.57 |
| Sex=female | 0.90 | 0.57 |
| Sex=male | 0.90 | 0.57 |
PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
| liters per hour (L/h) | All PK Participants_Roflumilast | All PK Participants_Roflumilast N-oxide |
|---|---|---|
| Weight=33.5 kg | 5.64 | 0.73 |
| Weight=70 kg | 5.64 | 0.89 |
| Weight=160 kg | 5.64 | 1.12 |
| Age=40 | 7.23 | 1.11 |
| Age=60 | 5.64 | 0.89 |
| Age=92 | 4.35 | 0.71 |
| Smoking=former | 5.64 | 0.89 |
| Smoking=current | 6.50 | 1.03 |
| Sex=female | 5.64 | 0.89 |
| Sex=male | 5.64 | 0.79 |
PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
| liters (L) | All PK Participants_Roflumilast | All PK Participants_Roflumilast N-oxide |
|---|---|---|
| Weight=33.5 kg | 26.0 | 4.5 |
| Weight=70 kg | 63.9 | 11.0 |
| Weight=160 kg | 175.2 | 30.2 |
| Age=40 | 63.9 | 11.0 |
| Age=60 | 63.9 | 11.0 |
| Age=92 | 63.9 | 11.0 |
| Smoking=former | 63.9 | 11.0 |
| Smoking=current | 63.9 | 11.0 |
| Sex=female | 63.9 | 11.0 |
| Sex=male | 63.9 | 11.0 |
PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.
| L | All PK Participants_Roflumilast | All PK Participants_Roflumilast N-oxide |
|---|---|---|
| Weight=33.5 kg | 69.6 | 5.0 |
| Weight=70 kg | 171.0 | 12.4 |
| Weight=160 kg | 468.8 | 34.0 |
| Age=40 | 171.0 | 12.4 |
| Age=60 | 171.0 | 12.4 |
| Age=92 | 171.0 | 12.4 |
| Smoking=former | 171.0 | 12.4 |
| Smoking=current | 171.0 | 12.4 |
| Sex=female | 171.0 | 12.4 |
| Sex=male | 171.0 | 12.4 |
tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.
| unitless | Roflumilast 500 μg OD | Roflumilast 500 μg EOD | Roflumilast 250 μg OD | Roflumilast 250 µg Down-Titration |
|---|---|---|---|---|
| Overall | 1.17 (0.366 to 2.05) | 0.608 (0.227 to 1.03) | 0.563 (0.157 to 1.01) | 0.583 (0.210 to 1.24) |
| Age < 65 (n=198,187,229,45) | 1.06 (0.323 to 1.85) | 0.559 (0.237 to 0.998) | 0.518 (0.160 to 0.958) | 0.511 (0.205 to 0.984) |
| Age ≥ 65 to < 75 (n=146,159,136,39) | 1.24 (0.550 to 2.08) | 0.660 (0.177 to 1.04) | 0.614 (0.138 to 1.10) | 0.683 (0.207 to 1.23) |
| Age ≥ 75 (n=48,53,39,17) | 1.24 (0.318 to 2.31) | 0.676 (0.188 to 1.12) | 0.616 (0.195 to 1.01) | 0.712 (0.300 to 1.32) |
| Weight < 60 kg (n=56,78,73,17) | 1.34 (0.591 to 2.64) | 0.755 (0.258 to 1.22) | 0.653 (0.156 to 1.12) | 0.934 (0.325 to 1.39) |
| Weight ≥ 60 kg (n=336,321,331,84) | 1.12 (0.339 to 1.99) | 0.592 (0.223 to 1.01) | 0.552 (0.158 to 0.971) | 0.538 (0.202 to 1.02) |
| Males (n=300,297,290,66) | 1.12 (0.363 to 1.96) | 0.585 (0.226 to 0.994) | 0.558 (0.145 to 0.998) | 0.575 (0.213 to 1.14) |
| Females (n=92,102,114,35) | 1.29 (0.468 to 2.38) | 0.696 (0.260 to 1.15) | 0.618 (0.189 to 1.01) | 0.626 (0.217 to 1.25) |
| Current Smoker (n=179,183,200,45) | 1.04 (0.327 to 1.88) | 0.568 (0.247 to 0.976) | 0.514 (0.101 to 0.949) | 0.554 (0.228 to 1.21) |
| Former Smoker (n=213,216,204,56) | 1.25 (0.416 to 2.15) | 0.632 (0.186 to 1.09) | 0.626 (0.196 to 1.10) | 0.624 (0.207 to 1.30) |
tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.
| unitless | Roflumilast 500 μg OD | Roflumilast 250 μg OD |
|---|---|---|
| All Participants (n=1114,76) | 1.17 (0.352 to 2.03) | 0.611 (0.197 to 1.243) |
| Discontinuation due to Any AEI=Yes (n=67,62) | 1.28 (0.427 to 2.22) | 0.647 (0.201 to 1.239) |
| Discontinuation due to Any AEI=No (n=1047,14) | 1.16 (0.339 to 2.02) | 0.436 (0.212 to 1.069) |
| Discontinuation due to Any AE=Yes (n=77,64) | 1.29 (0.464 to 2.10) | 0.647 (0.204 to 1.237) |
| Discontinuation due to Any AE=No (n=1037,12) | 1.16 (0.337 to 2.02) | 0.408 (0.209 to 1.006) |
| Discontinuation Due to Any Reason=Yes (n=106,75) | 1.23 (0.416 to 2.06) | 0.600 (0.197 to 1.243) |
| Discontinuation Due to Any Reason=No (n=1008,1) | 1.16 (0.332 to 2.02) | 0.626 (0.626 to 0.626) |
| At Least 1 AEI=Yes (n=536,75) | 1.23 (0.453 to 2.09) | 0.600 (0.197 to 1.243) |
| At Least 1 AEI=No (578,1) | 1.12 (0.297 to 1.98) | 0.929 (0.929 to 0.929) |
| At Least 1 AE=Yes (n=693,76) | 1.22 (0.416 to 2.07) | 0.611 (0.197 to 1.243) |
| At Least 1 AE=No (n=421,0) | 1.08 (0.294 to 1.97) | NA (NA to NA) |
The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)\] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.
| percentage of participants | Roflumilast 250 μg OD | Roflumilast 500 μg EOD | Roflumilast 500 μg OD |
|---|---|---|---|
| Weight=48 kg (tPDE4i=0.72,0.72,1.45) | 53.2 (0.352 to 2.03) | 53.2 (0.197 to 1.243) | 61.8 |
| Weight=74 kg (tPDE4i=0.65,0.65,1.30) | 52.3 (0.427 to 2.22) | 52.3 (0.201 to 1.239) | 60.1 |
| Weight=105 kg (tPDE4i=0.60.0.60,1.19) | 51.7 (0.339 to 2.02) | 51.7 (0.212 to 1.069) | 58.8 |
| Former Smoker (tPDE4i=0.65,0.65,1.30) | 52.3 (0.464 to 2.10) | 52.3 (0.204 to 1.237) | 60.1 |
| Current Smoker (tPDE4i=0.56,0.56,1.13) | 42.5 (0.337 to 2.02) | 42.5 (0.209 to 1.006) | 49.2 |
| Male (tPDE4i=0.65,0.65,1.30) | 52.3 (0.416 to 2.06) | 52.3 (0.197 to 1.243) | 60.1 |
| Female (tPDE4i=0.72,0.72,1.45) | 53.2 (0.332 to 2.02) | 53.2 (0.626 to 0.626) | 61.8 |
| Age=51 (tPDE4i=0.58,0.58,1.15) | 51.4 (0.453 to 2.09) | 51.4 (0.197 to 1.243) | 58.4 |
| Age=64 (tPDE4i=0.65,0.65,1.30) | 52.3 (0.297 to 1.98) | 52.3 (0.929 to 0.929) | 60.1 |
| Age=77 (tPDE4i=0.72,0.72,1.44) | 53.2 (0.416 to 2.07) | 53.2 (0.197 to 1.243) | 61.7 |
| With LAMA (tPDE4i=0.65,0.65,1.30) | 52.3 (0.294 to 1.97) | 52.3 (NA to NA) | 60.1 |
| Without LAMA (tPDE4i=0.65,0.65,1.30) | 43.5 | 43.5 | 51.4 |
The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility\] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.
| milliliters (mL) | Roflumilast 500 μg OD_CFB in FEV1 @ Week 4 | Roflumilast 500 μg OD_CFB in FEV1 @ Week 12 |
|---|---|---|
| Weight=33.5 kg (tPDE4i=1.012,1.012) | 50 (0.197 to 1.243) | 32 |
| Weight=70 kg (tPDE4i=0.839,0.839) | 60.5 (0.201 to 1.239) | 56 |
| Weight=160 kg (tPDE4i=0.681,0.681) | 108 (0.212 to 1.069) | 157 |
| Current Smoker (tPDE4i=0.729,0.729) | 99.5 (0.204 to 1.237) | 96.5 |
| Former/Never Smoker (tPDE4i=0.839,0.839) | 60.5 (0.209 to 1.006) | 56 |
| Male (tPDE4i=0.839,0.839) | 60.5 (0.197 to 1.243) | 56 |
| Female (tPDE4i=0.937,0.937) | 53.2 (0.626 to 0.626) | 49.8 |
| Age=40 years (tPDE4i=0.675,0.675) | 57.6 (0.197 to 1.243) | 52.2 |
| Age=60 years (tPDE4i=0.839,0.839) | 60.5 (0.929 to 0.929) | 56 |
| Age=92 years (tPDE4i=1.06,1.06) | 56.4 (0.197 to 1.243) | 53.3 |
| Asian (tPDE4i=0.839,0.839) | 56.1 (NA to NA) | 52 |
| non-Asian (tPDE4i=0.839,0.839) | 60.5 | 56 |
| COPD_Not Very Severe (tPDE4i=0.839,0.839) | 60.5 | 56 |
| COPD_Very Severe (tPDE4i=0.839,0.839) | 42.2 | 39.1 |
| LAMA=Yes (tPDE4i=0.839,0.839) | 60.5 | 56 |
| LAMA=No (tPDE4i=0.839,0.839) | 63.5 | 58.8 |
| %FEV1 Reversibility=-28% (tPDE4i=0.839,0.839) | 68.1 | 63.1 |
| %FEV1 Reversibility=10% (tPDE4i=0.839,0.839) | 60.5 | 56 |
| %FEV1 Reversibility=147% (tPDE4i=0.839,0.839) | 32.9 | 30.5 |
Collected over Main Treatment Period: First dose of study drug to 30 days past last dose or first dose in the Down-Titration Period (Up to 114 Days). Down-Titration Period: First dose of study drug to 30 days past the last dose of study drug (Up to 86 Days).. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast 250 μg OD Then 500 μg OD_Main Treatment Period | — | 19/441 (4.3%) | 239/441 (54.2%) |
| Roflumilast 500 μg EOD Then 500 μg OD_Main Treatment Period | — | 22/437 (5%) | 248/437 (56.8%) |
| Roflumilast 500 μg OD_Main Treatment Period | — | 20/443 (4.5%) | 272/443 (61.4%) |
| Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | — | 1/27 (3.7%) | 13/27 (48.1%) |
| Roflumilast 500 μg EOD_Down-Titration Period | — | 0/39 (0%) | 21/39 (53.8%) |
| Roflumilast 500 μg OD_Down Titration Period | — | 0/38 (0%) | 25/38 (65.8%) |
| Event | Roflumilast 250 μg OD Then 500 μg OD_Main Treatment Period | Roflumilast 500 μg EOD Then 500 μg OD_Main Treatment Period | Roflumilast 500 μg OD_Main Treatment Period | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 8/441 | 13/437 | 7/443 | 1/27 | 0/39 | 0/38 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/441 | 0/437 | 3/443 | 0/27 | 0/39 | 0/38 |
| PneumoniaInfections and infestations | 2/441 | 1/437 | 1/443 | 0/27 | 0/39 | 0/38 |
| Myocardial ischaemiaCardiac disorders | 0/441 | 1/437 | 1/443 | 0/27 | 0/39 | 0/38 |
| Atrial fibrillationCardiac disorders | 0/441 | 1/437 | 0/443 | 0/27 | 0/39 | 0/38 |
| Acute sinusitisInfections and infestations | 0/441 | 1/437 | 0/443 | 0/27 | 0/39 | 0/38 |
| Respiratory tract infectionInfections and infestations | 0/441 | 1/437 | 0/443 | 0/27 | 0/39 | 0/38 |
| Upper respiratory tract infectionInfections and infestations | 0/441 | 1/437 | 0/443 | 0/27 | 0/39 | 0/38 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/441 | 1/437 | 0/443 | 0/27 | 0/39 | 0/38 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 0/441 | 1/437 | 0/443 | 0/27 | 0/39 | 0/38 |
| Event | Roflumilast 250 μg OD Then 500 μg OD_Main Treatment Period | Roflumilast 500 μg EOD Then 500 μg OD_Main Treatment Period | Roflumilast 500 μg OD_Main Treatment Period | Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period | Roflumilast 500 μg EOD_Down-Titration Period | Roflumilast 500 μg OD_Down Titration Period |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 107/441 | 113/437 | 134/443 | 3/27 | 6/39 | 11/38 |
| Decreased appetiteMetabolism and nutrition disorders | 100/441 | 105/437 | 129/443 | 3/27 | 8/39 | 9/38 |
| HeadacheNervous system disorders | 107/441 | 115/437 | 115/443 | 2/27 | 7/39 | 10/38 |
| InsomniaPsychiatric disorders | 97/441 | 100/437 | 106/443 | 2/27 | 10/39 | 6/38 |
| NauseaGastrointestinal disorders | 87/441 | 92/437 | 110/443 | 1/27 | 5/39 | 8/38 |
| Abdominal painGastrointestinal disorders | 69/441 | 58/437 | 64/443 | 0/27 | 6/39 | 5/38 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 34/441 | 39/437 | 38/443 | 3/27 | 3/39 | 1/38 |
| Abdominal pain upperGastrointestinal disorders | 19/441 | 15/437 | 27/443 | 0/27 | 3/39 | 3/38 |
| NasopharyngitisInfections and infestations | 7/441 | 11/437 | 12/443 | 0/27 | 0/39 | 3/38 |
| TremorNervous system disorders | 0/441 | 0/437 | 0/443 | 2/27 | 1/39 | 0/38 |
Safety Analysis Set (SAS) included all randomized participants who took at least one dose of study medication. Main Treatment Period.
| Age, Continuous(years) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| Mean | 64.2 ± 7.81 | 65.0 ± 8.21 | 64.6 ± 8.36 | 64.6 ± 8.13 |
| Age, Customized(participants) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| 40-64 years | 242 | 202 | 224 | 668 |
| 65-84 years | 199 | 235 | 217 | 651 |
| 85 years and over | 0 | 0 | 2 | 2 |
| Sex: Female, Male(Participants) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| Female | 121 | 112 | 105 | 338 |
| Male | 320 | 325 | 338 | 983 |
| Race/Ethnicity, Customized(participants) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 5 | 8 |
| Not Hispanic or Latino | 428 | 423 | 426 | 1277 |
| Missing | 12 | 12 | 12 | 36 |
| Race/Ethnicity, Customized(participants) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| American Indian or Alaskan Native | 0 | 1 | 0 | 1 |
| Asian | 32 | 30 | 32 | 94 |
| Black or African American | 3 | 3 | 3 | 9 |
| Native Hawaiian/Other Pacific Islander | 1 | 4 | 3 | 8 |
| White | 405 | 399 | 405 | 1209 |
| Region of Enrollment(participants) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| Bulgaria | 36 | 18 | 30 | 84 |
| Germany | 12 | 24 | 16 | 52 |
| Greece | 8 | 6 | 6 | 20 |
| Hungary | 82 | 74 | 79 | 235 |
| Korea, Republic Of | 22 | 11 | 13 | 46 |
| Philippines | 7 | 13 | 10 | 30 |
| Poland | 60 | 68 | 71 | 199 |
| Romania | 54 | 46 | 44 | 144 |
| Russia | 37 | 48 | 55 | 140 |
| Slovakia | 40 | 38 | 27 | 105 |
| South Africa | 17 | 18 | 26 | 61 |
| Spain | 2 | 2 | 1 | 5 |
| Thailand | 2 | 6 | 9 | 17 |
| Ukraine | 56 | 58 | 54 | 168 |
| United Kingdom | 6 | 7 | 2 | 15 |
| Height(cm) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| Mean | 169.1 ± 8.73 | 168.8 ± 8.66 | 169.1 ± 8.55 | 169.0 ± 8.64 |
| Weight(kg) | Roflumilast 250 μg OD Then 500 μg OD | Roflumilast 500 μg EOD Then 500 μg OD | Roflumilast 500 μg OD | Total |
|---|---|---|---|---|
| Mean | 75.59 ± 18.627 | 74.31 ± 17.808 | 75.68 ± 16.949 | 75.20 ± 17.804 |
5 further baseline measures are reported on the registry.
Ran from May 2014 to primary completion in Sep 2015, 16 months.
Results were first posted in Mar 2017, 1 year 6 months after primary completion.
Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 16 months is below that.
Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →